TY - JOUR
T1 - CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration
AU - Imai, Daisuke
AU - Mori, Keisuke
AU - Horie-Inoue, Kuniko
AU - Gehlbach, Peter L.
AU - Awata, Takuya
AU - Inoue, Satoshi
AU - Yoneya, Shin
N1 - Funding Information:
Acknowledgment This research was supported in part by a grant from an Institutional Grant from the Medical Research Center, Saitama Medical University (KM) and a grant-in-aid for scientific research (21592242) from the Ministry of Education, Culture and Science in Japan (KM).
PY - 2010/6
Y1 - 2010/6
N2 - We determined whether there is an association between complement factor H (CFH), high-temperature requirement A-1 (HTRA1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor (PEDF) genotypes and the response to treatment with a single intravitreous injection of bevacizumab for agerelated macular degeneration (AMD). Eighty-three patients with exudative AMD treated by bevacizumab injection were genotyped for three single nucleotide polymorphisms (SNPs; rs800292, rs1061170, rs1410996) in the CFH gene, a rs11200638-SNP in the HTRA1 gene, three SNPs (rs699947, rs1570360, rs2010963) in the VEGF gene, and four SNPs (rs12150053, rs12948385, rs9913583, rs1136287) in the PEDF gene using a TaqMan assay. The CT genotype (heterozygous) of CFH-rs1061170 was more frequently represented in nonresponders in vision than TT genotypes (nonrisk allele homozygous) at the time points of 1 and 3 months, while there was no CC genotype (risk allele homozygous) in our study cohort (p=7.66 × 10-3, 7.83 × 10-3, respectively). VEGF-rs699947 was also associated with vision changes at 1 month and PEDF-rs1136287 at 3 months (p=5.11 × 10-3, 2.05 × 10- 2, respectively). These variants may be utilized for genetic biomarkers to estimate visual outcomes in the response to intravitreal bevacizumab treatment for AMD.
AB - We determined whether there is an association between complement factor H (CFH), high-temperature requirement A-1 (HTRA1), vascular endothelial growth factor (VEGF), and pigment epithelium-derived factor (PEDF) genotypes and the response to treatment with a single intravitreous injection of bevacizumab for agerelated macular degeneration (AMD). Eighty-three patients with exudative AMD treated by bevacizumab injection were genotyped for three single nucleotide polymorphisms (SNPs; rs800292, rs1061170, rs1410996) in the CFH gene, a rs11200638-SNP in the HTRA1 gene, three SNPs (rs699947, rs1570360, rs2010963) in the VEGF gene, and four SNPs (rs12150053, rs12948385, rs9913583, rs1136287) in the PEDF gene using a TaqMan assay. The CT genotype (heterozygous) of CFH-rs1061170 was more frequently represented in nonresponders in vision than TT genotypes (nonrisk allele homozygous) at the time points of 1 and 3 months, while there was no CC genotype (risk allele homozygous) in our study cohort (p=7.66 × 10-3, 7.83 × 10-3, respectively). VEGF-rs699947 was also associated with vision changes at 1 month and PEDF-rs1136287 at 3 months (p=5.11 × 10-3, 2.05 × 10- 2, respectively). These variants may be utilized for genetic biomarkers to estimate visual outcomes in the response to intravitreal bevacizumab treatment for AMD.
KW - Age-related macular degeneration
KW - Bevacizumab
KW - Complement factor H
KW - Genetic biomarker
KW - High-temperature requirement A-1
KW - Pigment epitheliumderived factor
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=79955796065&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955796065&partnerID=8YFLogxK
U2 - 10.1007/s12177-010-9055-1
DO - 10.1007/s12177-010-9055-1
M3 - Article
C2 - 21811649
AN - SCOPUS:79955796065
SN - 1936-8437
VL - 3
SP - 53
EP - 59
JO - Journal of Ocular Biology, Diseases, and Informatics
JF - Journal of Ocular Biology, Diseases, and Informatics
IS - 2
ER -